Modafinil In Multiple Sclerosis Fatigue

  1. Efficacy and safety of Modafinil (Provigil) for the treatment of Fatigue in Multiple Sclerosis: a two center phase 2 study
    J Neurol NeuroSurg Psychiatry 2002 Feb;72(2):179-83

  1. Modafinil for Fatigue in MS: A randomized placebo-controlled double-blind study
    Neurology 2005 Apr 12;64(7):1139-43

  2. Modafinil in treatment of Fatigue in Multiple Sclerosis Results of an open-label study
    J Neurol 2002 Jul;249(8):983-7


Modafinil For Fatigue In MS: A Randomized Placebo-Controlled Double-Blind Study

French Modafinil Study Group
Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L, Moreau T, Pelletier J, Lubetzki C, Clanet M
Neurology 2005 Apr 12;64(7):1139-43
Hopital de la Salpetriere, Federation de Neurologie, AP-HP, Paris, France
PMID# 15824337

To assess whether Modafinil, a wakefulness-promoting agent, is useful for Fatigue in patients with Multiple Sclerosis (MS).

Patients with MS with stable disability, and a baseline score of 45 or more on the Modified Fatigue Impact Scale (MFIS), were eligible for the 5-week randomized, double-blind, placebo-controlled, parallel group study.

The initial daily dose of Modafinil was 200 mg for 1 week.

Depending on tolerance, the dose was increased by 100 mg every week up to 400 mg/day and remained unchanged between day 21 and day 35. The primary outcome variable was the change of MFIS score at day 35.

A total of 115 patients with MS were enrolled in the study and in the intention to treat analysis.

The mean MFIS score at baseline was 63 +/- 9 in the placebo group and 63 +/- 10 in the Modafinil group.

MFIS scores improved between day 0 and day 35 in both placebo-treated and Modafinil-treated groups, but no significant difference was detected between the two groups. There was no major safety concern.

There was no improvement of Fatigue in patients with Multiple Sclerosis treated with Modafinil vs placebo according to the Modified Fatigue Impact Scale.


Modafinil In Treatment Of Fatigue In Multiple Sclerosis Results Of An Open-Label Study

Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM
J Neurol 2002 Jul;249(8):983-7
Arbeitskreis fur klinische Forschung in der Neurorehabilitation Kurhausstr. 100 2222 Bad Pirawarth, Austria
PMID# 12195441

Modafinil is a unique wake-promoting agent that is chemically distinct from traditional stimulants.

Results of a placebo-controlled study showed it to improve Fatigue in Multiple Sclerosis (MS) at a dose of 200 mg daily, but not at a dose of 400 mg daily.

To establish the efficacy, safety and appropriate dose of Modafinil in the treatment of Fatigue and sleepiness in patients with Multiple Sclerosis.

A total of 50 patients diagnosed with MS (mean age 40.4 +/- 10.3 years, 30 females/20 males.

MS type: 36 Relapsing/Remitting, 1 Primary/Progressive, 13 Secondary/Progressive; mean disability level 3.8 +/- 1.5 on the Kurtzke EDSS) and complaining of chronic Fatigue were enrolled in a prospective 3-month, two-center, open-label study.

Efficacy was evaluated with the Fatigue Severity Scale (FSS, score range 0-42), the Epworth Sleepiness Scale (ESS, score range 0-24).

And by subjective patient appraisal of change of Fatigue, quality of life and overall satisfaction with treatment. Adverse Effects (AEs) were recorded throughout the study.

Treatment was started with a single daily dose of 100 mg in all patients. In non-responders the dose was increased by 100 mg increments up to a maximum daily dose of 400 mg.

Three patients discontinued Modafinil because of AEs (Nervousness, Dizziness). Two patients (4 %) were treated with 50 mg, 25 (50 %) with 100 mg, 21 (42 %) with 200 mg and 2 (4 %) with 300 mg daily.

No patient required 400 mg daily. Mean FSS scores were 30.3 +/- 8.5 at baseline and 25.4 +/- 3.7 at 3 months (p < 0.0001).

Mean ESS scores were 9.7 +/- 3.9 at baseline and 4.9 +/- 2.9 at 3 months (p < 0.0001).

Self-appraisal of change of Fatigue showed clear improvement in 41 patients (87.2 %), some improvement in 4 (8.5 %) and no change in 2 (4.3 %).

Overall clinical condition was clearly improved in 43 patients (91.5 %), somewhat improved in 1 patient (2.1 %), and unchanged in 3 patients (6.4 %).

No patient reported worsening of overall clinical condition.

Treatment with Modafinil significantly improves Fatigue and sleepiness and is well tolerated by patients with MS.

Unlike the higher dose regimen required in Narcolepsy, a low-dose regimen of Modafinil is effective in MS.

Medical Texts
Anatomy | Immune System | Lymphocytes | Meds
MHC | Movement | Cranial Nerves | Physiology

MS Glossary ThJuland's MSers' Glen - Our CyberHome Page Top The Glen's Gallery: Come & Share Our Stories MS Files MS Abstracts Site Index

ANS | Bladder | Cognition | Fatigue | Fluid | Genetics
Interferons | IVIG | Nitric Oxide | Optic Neuritis | Pain
Physiology | Prions | Prognosis | ReMyelinate | Steroids
Stress | Treatments | TNF | Uric Acid | Viruses

Copyright 1997 - 2010:
Permission is granted to MS Societies and all MSers to utilize information from these pages provided that no financial reward is gained and attribution is given to the author/s.